Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEE S CLORE

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1609873553
CMS profile
299161
Location
OWENSBORO, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$162,214.35

234 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEE S CLORE

NPI 1609873553 · CMS profile ID 299161

Allopathic & Osteopathic Physicians / Allergy & Immunology

OWENSBORO, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609873553?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEE S CLORE, NPI 1609873553, CMS profile ID 299161. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609873553?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LEE S CLORE, NPI 1609873553, CMS profile ID 299161. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609873553?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LEE S CLORE, NPI 1609873553, CMS profile ID 299161, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 234 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1609873553?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

234 matching records · $162,214.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 234 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 234.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $942.0005/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128061 CMS
Amgen Inc. $15.1205/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019999407 CMS
GENZYME CORPORATION $20.5605/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049826857 CMS
Regeneron Healthcare Solutions, Inc. $8.0005/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128049 CMS
Regeneron Healthcare Solutions, Inc. $12.5505/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128053 CMS
Regeneron Healthcare Solutions, Inc. $150.6505/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128057 CMS
Pharming Healthcare, Inc. $0.9204/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029327925 CMS
Pharming Healthcare, Inc. $0.4304/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029327933 CMS
Pharming Healthcare, Inc. $1.4004/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029327943 CMS
Pharming Healthcare, Inc. $14.0004/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029327951 CMS
Pharming Healthcare, Inc. $71.2904/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029327961 CMS
Pharming Healthcare, Inc. $17.6704/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029327897 CMS
Pharming Healthcare, Inc. $650.7904/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029327907 CMS
Pharming Healthcare, Inc. $58.9504/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029327915 CMS
Regeneron Healthcare Solutions, Inc. $1,178.0004/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128045 CMS
GENZYME CORPORATION $1,649.0004/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049826837 CMS
GlaxoSmithKline, LLC. $3,900.0004/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003256565 CMS
GlaxoSmithKline, LLC. $3,900.0004/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003256979 CMS
GlaxoSmithKline, LLC. $17.0504/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003256303 CMS
GlaxoSmithKline, LLC. $512.2104/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003256991 CMS
GlaxoSmithKline, LLC. $43.8904/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003257277 CMS
GENZYME CORPORATION $20.1204/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049826827 CMS
Genentech USA, Inc. $15.8904/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040435625 CMS
GlaxoSmithKline, LLC. $125.0004/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003256013 CMS
GlaxoSmithKline, LLC. $8.0004/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003257227 CMS
GlaxoSmithKline, LLC. $226.0104/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003257269 CMS
kaleo, Inc. $19.0804/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013046001 CMS
GlaxoSmithKline, LLC. $57.0004/11/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061461712 CMS
Regeneron Healthcare Solutions, Inc. $12.5104/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128025 CMS
Regeneron Healthcare Solutions, Inc. $101.8004/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128029 CMS
Regeneron Healthcare Solutions, Inc. $450.2304/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128033 CMS
Regeneron Healthcare Solutions, Inc. $726.4004/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128037 CMS
Regeneron Healthcare Solutions, Inc. $158.5104/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128041 CMS
Grifols USA, LLC $15.3403/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011855405 CMS
GENZYME CORPORATION $3.8703/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049826815 CMS
Regeneron Healthcare Solutions, Inc. $2,473.0003/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128021 CMS
GENZYME CORPORATION $19.0903/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049826811 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.4803/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055370315 CMS
Regeneron Healthcare Solutions, Inc. $498.1303/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128017 CMS
AstraZeneca Pharmaceuticals LP $15.9503/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024994587 CMS
GlaxoSmithKline, LLC. $15.2503/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003256987 CMS
AstraZeneca Pharmaceuticals LP $76.1603/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025037335 CMS
PFIZER INC. $3.3203/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050599749 CMS
GENZYME CORPORATION $22.2503/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049826807 CMS
AstraZeneca Pharmaceuticals LP $13.0303/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025029951 CMS
Regeneron Healthcare Solutions, Inc. $1,178.0003/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999128015 CMS
Pharming Healthcare, Inc. $900.0003/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029327889 CMS
GlaxoSmithKline, LLC. $975.0002/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003256959 CMS
GENZYME CORPORATION $1,649.0002/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049826795 CMS
GlaxoSmithKline, LLC. $15.5902/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003256289 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $36,494.49 126
PY2020 $51,673.70 117
PY2021 $88,057.49 149
PY2022 $117,042.90 216
PY2023 $162,214.35 234
PY2024 $190,979.46 210
PY2025 $195,009.00 273

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $687,976.67 300
PY2024 Principal investigator $529,612.45 128
PY2023 Principal investigator $357,233.62 74
PY2022 Principal investigator $360,097.09 102
PY2021 Principal investigator $438,058.63 106
PY2020 Recipient $9,153.58 1
PY2020 Principal investigator $301,882.65 22
PY2019 Recipient $1,764.23 1
PY2019 Principal investigator $165,651.61 36

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

300 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $1,778.40 12/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192149319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $187.20 12/24/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184280304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,320.41 12/19/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,145.43 12/19/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,552.94 12/19/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 12/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184275259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 12/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184275261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 12/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184275263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 12/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184275265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 12/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184275267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 12/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184275269
Principal investigator 1 GENZYME CORPORATION $71.00 12/08/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $728.44 11/20/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184263611
Principal investigator 1 GlaxoSmithKline, LLC. $185.23 11/19/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192149328
Principal investigator 1 GlaxoSmithKline, LLC. $386.10 11/19/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192156836
Principal investigator 1 GlaxoSmithKline, LLC. $257.40 11/19/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $525.33 11/19/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262177
Principal investigator 1 GlaxoSmithKline, LLC. $1,287.00 11/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192149311
Principal investigator 1 GlaxoSmithKline, LLC. $2,444.00 11/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192156840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 11/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184260565
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 11/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192155738
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 11/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192155746
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 11/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180925
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 11/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192188001
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192189217
Principal investigator 1 SANOFI US SERVICES INC. $669.60 11/12/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124103
Principal investigator 1 GlaxoSmithKline, LLC. $1,139.98 11/06/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192153550
Principal investigator 1 GlaxoSmithKline, LLC. $130.00 11/04/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192150955
Principal investigator 1 GlaxoSmithKline, LLC. $1,443.00 11/04/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192153558
Principal investigator 1 GlaxoSmithKline, LLC. $323.00 11/04/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192155757
Principal investigator 1 GlaxoSmithKline, LLC. $2,496.00 11/04/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192156828
Principal investigator 1 GlaxoSmithKline, LLC. $1,029.60 11/04/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192185335
Principal investigator 1 GlaxoSmithKline, LLC. $3,679.00 11/04/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192185362
Principal investigator 1 GlaxoSmithKline, LLC. $1,158.30 11/04/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192189213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $728.44 10/23/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184252446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,069.74 10/16/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184250947
Principal investigator 1 GENZYME CORPORATION $2,877.00 10/15/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $728.44 10/09/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184249164
Principal investigator 1 GlaxoSmithKline, LLC. $1,157.40 10/08/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192184659
Principal investigator 1 SANOFI US SERVICES INC. $2,259.90 10/08/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,198.00 10/03/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184244911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 09/29/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184243549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 09/29/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184243551
Principal investigator 1 Eli Lilly and Company $37,442.00 09/22/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187880523
Principal investigator 1 GlaxoSmithKline, LLC. $1,078.20 09/18/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192188004
Principal investigator 1 GlaxoSmithKline, LLC. $11,503.85 09/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192189231
Principal investigator 1 SANOFI US SERVICES INC. $8,438.40 09/12/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124080
Principal investigator 1 GlaxoSmithKline, LLC. $3,870.00 09/08/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192185348
Principal investigator 1 GENZYME CORPORATION $44.45 09/05/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,483.39 09/04/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184235357
Principal investigator 1 GlaxoSmithKline, LLC. $689.00 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192098189
Principal investigator 1 GlaxoSmithKline, LLC. $468.00 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192098213
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192149300
Principal investigator 1 GlaxoSmithKline, LLC. $3,088.80 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192149315
Principal investigator 1 GlaxoSmithKline, LLC. $457.60 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192153541
Principal investigator 1 GlaxoSmithKline, LLC. $65.00 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192155742
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192184654
Principal investigator 1 GlaxoSmithKline, LLC. $457.60 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192184667
Principal investigator 1 GlaxoSmithKline, LLC. $32.50 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192184669
Principal investigator 1 GlaxoSmithKline, LLC. $514.80 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192187312
Principal investigator 1 GlaxoSmithKline, LLC. $91.00 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192188008
Principal investigator 1 GlaxoSmithKline, LLC. $514.80 09/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192188014
Principal investigator 1 SANOFI US SERVICES INC. $92.10 09/03/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124087
Principal investigator 1 GlaxoSmithKline, LLC. $2,585.70 08/27/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192189226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,656.09 08/26/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184230675
Principal investigator 1 GlaxoSmithKline, LLC. $20,949.79 08/15/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192153561
Principal investigator 1 GENZYME CORPORATION $1,117.00 08/04/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124077
Principal investigator 1 GlaxoSmithKline, LLC. $1,767.60 08/01/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192180914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,139.48 07/31/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE No dispute reported 06/30/2026 1184222716
Principal investigator 1 GlaxoSmithKline, LLC. $1,355.40 07/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192153571
Principal investigator 1 GlaxoSmithKline, LLC. $7,576.44 07/22/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192153554
Principal investigator 1 SANOFI US SERVICES INC. $44.45 07/18/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124058
Principal investigator 1 Eli Lilly and Company $6,425.05 07/17/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187876269
Principal investigator 1 GlaxoSmithKline, LLC. $15,373.21 07/16/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180931
Principal investigator 1 GENZYME CORPORATION $3,006.00 07/11/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124072
Principal investigator 1 GENZYME CORPORATION $44.45 07/09/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124061
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,500.00 07/08/2025 Non-covered Recipient Entity
ALLERGY ASTHMA SPECIALISTS PSC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190300165
Principal investigator 1 Eli Lilly and Company $4,500.00 07/07/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A STUDY OF LY3454738 IN THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187872541
Principal investigator 1 SANOFI US SERVICES INC. $4,534.20 07/07/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 07/02/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 07/02/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 07/02/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212603
Principal investigator 1 GENZYME CORPORATION $94.45 06/18/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124065
Principal investigator 1 GENZYME CORPORATION $6,976.00 06/18/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124068
Principal investigator 1 GlaxoSmithKline, LLC. $26,089.42 06/17/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192098195
Principal investigator 1 GlaxoSmithKline, LLC. $4,080.60 06/16/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192156844
Principal investigator 1 Novartis Pharmaceuticals Corporation $66,084.04 06/15/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS, PSC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190301809
Principal investigator 1 GENZYME CORPORATION $991.00 06/11/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124031
Principal investigator 1 SANOFI US SERVICES INC. $1,814.40 06/11/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124036
Principal investigator 1 Eli Lilly and Company $14,972.00 06/10/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187875909
Principal investigator 1 GENZYME CORPORATION $7,959.00 06/09/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124025
Principal investigator 1 GlaxoSmithKline, LLC. $88.90 06/06/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187326
Principal investigator 1 GENZYME CORPORATION $5,992.00 05/21/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124021
Principal investigator 1 SANOFI US SERVICES INC. $1,814.40 05/19/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124043
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 05/16/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124040
Principal investigator 1 GlaxoSmithKline, LLC. $54,954.90 05/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192155753
Principal investigator 1 GlaxoSmithKline, LLC. $126.88 05/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192156824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,500.00 05/08/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184193941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,535.00 05/08/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184193943
Principal investigator 1 Eli Lilly and Company $24,051.00 05/07/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187880521
Principal investigator 1 GlaxoSmithKline, LLC. $1,506.60 05/05/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192188023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 04/28/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 04/28/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 04/28/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 04/28/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 04/28/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184189999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $118.75 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31.25 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17.50 04/25/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190135
Principal investigator 1 GlaxoSmithKline, LLC. $4,283.72 04/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192153546
Principal investigator 1 SANOFI US SERVICES INC. $6,700.50 04/21/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226124016
Principal investigator 1 GlaxoSmithKline, LLC. $6,678.24 04/10/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192189240
Principal investigator 1 GlaxoSmithKline, LLC. $128.70 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192098220
Principal investigator 1 GlaxoSmithKline, LLC. $228.80 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192149332
Principal investigator 1 GlaxoSmithKline, LLC. $228.80 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192156832
Principal investigator 1 GlaxoSmithKline, LLC. $457.60 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180922
Principal investigator 1 GlaxoSmithKline, LLC. $114.40 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192184646
Principal investigator 1 GlaxoSmithKline, LLC. $514.80 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192184663
Principal investigator 1 GlaxoSmithKline, LLC. $114.40 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192185344
Principal investigator 1 GlaxoSmithKline, LLC. $257.40 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192185353
Principal investigator 1 GlaxoSmithKline, LLC. $114.40 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192185367
Principal investigator 1 GlaxoSmithKline, LLC. $128.70 04/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192187317
Principal investigator 1 GlaxoSmithKline, LLC. $898.00 04/04/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192155761
Principal investigator 1 GlaxoSmithKline, LLC. $580.00 04/04/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192188018
Principal investigator 1 GlaxoSmithKline, LLC. $898.00 04/04/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189222
Principal investigator 1 SANOFI US SERVICES INC. $84.58 03/21/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1226124001
Principal investigator 1 GENZYME CORPORATION $1,171.00 03/17/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124008
Principal investigator 1 SANOFI US SERVICES INC. $1,814.40 03/10/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226123991
Principal investigator 1 GlaxoSmithKline, LLC. $643.00 03/07/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192149323
Principal investigator 1 GlaxoSmithKline, LLC. $753.00 03/07/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192180918
Principal investigator 1 GlaxoSmithKline, LLC. $1,624.00 03/07/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192184642
Principal investigator 1 GlaxoSmithKline, LLC. $1,624.00 03/07/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187309
Principal investigator 1 GlaxoSmithKline, LLC. $753.00 03/07/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187336
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,112.66 02/27/2025 Non-covered Recipient Entity
ALLERGY ASTHMA SPECIALISTS PSC
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190300163
Principal investigator 1 Eli Lilly and Company $1,240.88 02/25/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187876271
Principal investigator 1 Eli Lilly and Company $5,626.00 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187880525
Principal investigator 1 GlaxoSmithKline, LLC. $338.00 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192098178
Principal investigator 1 GlaxoSmithKline, LLC. $257.40 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192098181
Principal investigator 1 GlaxoSmithKline, LLC. $386.10 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192098209
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192155749
Principal investigator 1 GlaxoSmithKline, LLC. $257.40 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192156854
Principal investigator 1 GlaxoSmithKline, LLC. $8,185.96 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180906
Principal investigator 1 GlaxoSmithKline, LLC. $91.00 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192184649
Principal investigator 1 GlaxoSmithKline, LLC. $325.00 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192185339
Principal investigator 1 GlaxoSmithKline, LLC. $128.70 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192187331
Principal investigator 1 GlaxoSmithKline, LLC. $386.10 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192187993
Principal investigator 1 GlaxoSmithKline, LLC. $364.00 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192187997
Principal investigator 1 GlaxoSmithKline, LLC. $257.40 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192189209
Principal investigator 1 GlaxoSmithKline, LLC. $128.70 02/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192189235
Principal investigator 1 GENZYME CORPORATION $4,203.00 02/14/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124013
Principal investigator 1 Eli Lilly and Company $63,660.00 02/11/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187875935
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 02/11/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192098203
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 02/11/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192187305
Principal investigator 1 GlaxoSmithKline, LLC. $580.00 02/07/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192155765
Principal investigator 1 GlaxoSmithKline, LLC. $1,860.00 02/07/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192156849
Principal investigator 1 GENZYME CORPORATION $19,821.00 02/04/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226123996
Principal investigator 1 SANOFI US SERVICES INC. $4,356.51 02/04/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab No dispute reported 06/30/2026 1226123988
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 01/31/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184151262
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 01/31/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184151553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 01/31/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184151555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $362.31 01/31/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184151557
Principal investigator 1 GENZYME CORPORATION $360.00 01/30/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226124004
Principal investigator 1 GlaxoSmithKline, LLC. $2,991.25 01/30/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192149305
Principal investigator 1 GlaxoSmithKline, LLC. $10,017.36 01/28/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192185358
Principal investigator 1 Eli Lilly and Company $852.61 01/27/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187871535
Principal investigator 1 SANOFI US SERVICES INC. $6,516.90 01/23/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226123984
Principal investigator 1 SANOFI US SERVICES INC. $203.85 01/17/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226123975
Principal investigator 1 SANOFI US SERVICES INC. $169.19 01/17/2025 Non-covered Recipient Entity
Allergy And Asthma Specialists, Psc
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze No dispute reported 06/30/2026 1226123980
Principal investigator 1 GlaxoSmithKline, LLC. $4,006.80 01/13/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA SPECIALISTS PSC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192153566
Principal investigator 1 GlaxoSmithKline, LLC. $1,982.62 01/09/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS PSC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192187321
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,891.98 01/07/2025 Non-covered Recipient Entity
ALLERGY ASTHMA SPECIALISTS PSC
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled No dispute reported 06/30/2026 1190300167
Principal investigator 1 AstraZeneca UK Limited $8,867.91 01/06/2025 Non-covered Recipient Entity
ALLERGY ASTHMA SPECIALISTS PS
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185537485
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,983.33 01/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS, PSC
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190301807
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,683.33 01/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS, PSC
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled No dispute reported 06/30/2026 1190301811
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,608.48 01/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA SPECIALISTS, PSC
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co No dispute reported 06/30/2026 1190301813